Cancer Genetics and Epigenetics 2024, Vol.12, No.6, 306-316 http://medscipublisher.com/index.php/cge 315 Omar H., and Tolba M., 2019, Tackling molecular targets beyond PD-1/PD-l1: novel approaches to boost patients' response to cancer immunotherapy, Critical Reviews In Oncology/Hematology, 135: 21-29. https://doi.org/10.1016/j.critrevonc.2019.01.009 Page D.B., Kim I.K., Chun B., Redmond W.L., Martel M., Mori M., Wadell D., Moxon N., Mellinger S.L., Urba W.J., Gucalp A., and Traina T.A., 2019, A Phase II study of dual immune checkpoint blockade (ICB) plus androgen receptor (AR) blockade to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer (MBC), Journal of Clinical Oncology, 37(15): TPS1106-TPS1106.4 https://doi.org/10.1200/JCO.2019.37.15_SUPPL.TPS1106 Patience S., Chang X., Liu Z., Wu Y.L., and Zuo D.Y., 2021, The recent advances Of PD-1 and PD-l1 checkpoint signaling inhibition for breast cancer immunotherapy, European Journal of Pharmacology, 895: 173867. https://doi.org/10.1016/j.ejphar.2021.173867 PMID: 33460617 Qi Y.J., Yan X., Wang C., Cao H., and Liu G.X., 2022, Predictive value of PD-L1 Expression to the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer: a systematic review and meta-analysis, Frontiers in Pharmacology, 13: 1004821. https://doi.org/10.3389/fphar.2022.1004821 PMID: 36532783 PMCID: PMC9755205 Schmid P., Loirat D., Savas P., Espinosa E., Boni V., Italiano A., White S., Singel S.M., Withana N., Mani A., Li S., Harris A., Wongchenko M., and Sablin M., 2019, Abstract Ct049: Phase Ib Study Evaluating a Triplet Combination Of Ipatasertib (IPAT), Atezolizumab (atezo), and Paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC), Clinical Trials, 79(13_Supplement): CT049-CT049. https://doi.org/10.1158/1538-7445.AM2019-CT049 Schmid P., Savas P., Espinosa E., Boni V., Italiano A., White S., Cheng K., Lam L., Robert L., Laliman V., Shah K., and Sablin M., 2021, Abstract Ps12-28: phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab, and a taxane as first-line therapy for locally advanced/metastatic triple-negative breast cancer (TNBC), Cancer Research, 81(4_Supplement): PS12-28. https://doi.org/10.1158/1538-7445.SABCS20-PS12-28 Semba T., Xie X.M., Cohen E., Reuben J., Dalby K.N., Wang X.P., and Ueno N.T., 2020, Abstract 5067: suppression of tumorigenicity and metastasis of triple-negative breast cancer (TNBC) by c-Jun N-Terminal Kinase (JNK) inhibitor via reversing immunosuppressive tumor microenvironment (TME), Cancer Research, 80(16_Supplement): 5067. https://doi.org/10.1158/1538-7445.am2020-5067 Simmons C.E., Brezden-Masley C., Mccarthy J., Mcleod D., and Joy A.A., 2020, Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer, Therapeutic Advances in Medical Oncology, 12: 1758835920909091. https://doi.org/10.1177/1758835920909091 PMID: 33014143 PMCID: PMC7517981 Singh S., Numan A., Maddiboyina B., Arora S., Riadi Y., Md S., Alhakamy N., and Kesharwani P., 2021, The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer, Drug Discovery Today, 26(7): 1721-1727. https://doi.org/10.1016/j.drudis.2021.03.011 PMID: 33745879 Stanowska O., Kuczkiewicz-Siemion O., Debowska M., Olszewski W., Jagiełło-Gruszfeld A., Tysarowski A., and Prochorec-Sobieszek M., 2022, PD-L1-positive high-grade triple-negative breast cancer patients respond better to standard neoadjuvant treatment-a retrospective study of PD-L1 expression in relation to different clinicopathological parameters, Journal of Clinical Medicine, 11(19): 5524. https://doi.org/10.3390/jcm11195524 PMID: 36233396 PMCID: PMC9573147 Teo Z.L., Versaci S., Dushyanthen S., Caramia F., Savas P., Mintoff C.P., Zethoven M., Virassamy B., Luen S.J., Mcarthur G., Phillips W.A., Darcy P.K., and Loi S., 2017, Combined Cdk4/6 and Pi3kα inhibition is synergistic and immunogenic in triple-negative breast cancer, Cancer Research, 77(22): 6340-6352. https://doi.org/10.1158/0008-5472.CAN-17-2210 PMID: 28947417 Thomas R., Al-Khadairi G., and Decock J., 2021, Immune checkpoint inhibitors in triple negative breast cancer treatment: promising future prospects, Frontiers In Oncology, 10: 600573.. https://doi.org/10.3389/fonc.2020.600573 PMID: 33718107 PMCID: PMC7947906 Tomioka N., Azuma M., Ikarashi M., Yamamoto M., Sato M., Watanabe Kk., Yamashiro K., and Takahashi M., 2017, The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC), Breast Cancer, 25(1): 34-42. https://doi.org/10.1007/s12282-017-0781-0 PMID: 28488168 Uchimiak K., Badowska-Kozakiewicz A.M., Sobiborowicz-Sadowska A., and Deptała A., 2022, Current state of knowledge on the immune checkpoint inhibitors in triple-negative breast cancer treatment: approaches, efficacy, and challenges, Clinical Medicine Insights, Oncology, 16: 11795549221099869. https://doi.org/10.1177/11795549221099869 PMID: 35721387 PMCID: PMC9201309
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==